Cargando…

Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders

BACKGROUND: Neurodevelopmental disorders (NDDs) are a group of heterogeneous conditions, which include mainly intellectual disability, developmental delay (DD) and autism spectrum disorder (ASD), among others. These diseases are highly heterogeneous and both genetic and environmental factors play an...

Descripción completa

Detalles Bibliográficos
Autores principales: Álvarez-Mora, María Isabel, Sánchez, Aurora, Rodríguez-Revenga, Laia, Corominas, Jordi, Rabionet, Raquel, Puig, Susana, Madrigal, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858550/
https://www.ncbi.nlm.nih.gov/pubmed/35183220
http://dx.doi.org/10.1186/s13023-022-02213-z
_version_ 1784654265269092352
author Álvarez-Mora, María Isabel
Sánchez, Aurora
Rodríguez-Revenga, Laia
Corominas, Jordi
Rabionet, Raquel
Puig, Susana
Madrigal, Irene
author_facet Álvarez-Mora, María Isabel
Sánchez, Aurora
Rodríguez-Revenga, Laia
Corominas, Jordi
Rabionet, Raquel
Puig, Susana
Madrigal, Irene
author_sort Álvarez-Mora, María Isabel
collection PubMed
description BACKGROUND: Neurodevelopmental disorders (NDDs) are a group of heterogeneous conditions, which include mainly intellectual disability, developmental delay (DD) and autism spectrum disorder (ASD), among others. These diseases are highly heterogeneous and both genetic and environmental factors play an important role in many of them. The introduction of next generation sequencing (NGS) has lead to the detection of genetic variants in several genetic diseases. The main aim of this report is to discuss the impact and advantages of the implementation of NGS in the diagnosis of NDDs. Herein, we report diagnostic yields of applying whole exome sequencing in 87 families affected by NDDs and additional data of whole genome sequencing (WGS) from 12 of these families. RESULTS: The use of NGS technologies allowed identifying the causative gene alteration in approximately 36% (31/87) of the families. Among them, de novo mutation represented the most common cause of genetic alteration found in 48% (15/31) of the patients with diagnostic mutations. The majority of variants were located in known neurodevelopmental disorders genes. Nevertheless, some of the diagnoses were made after the use of GeneMatcher tools which allow the identification of additional patients carrying mutations in THOC2, SETD1B and CHD9 genes. Finally the use of WGS only allowed the identification of disease causing variants in 8% (1/12) of the patients in which previous WES failed to identify a genetic aetiology. CONCLUSION: NGS is more powerful in identifying causative pathogenic variant than conventional algorithms based on chromosomal microarray as first-tier test. Our results reinforce the implementation of NGS as a first-test in genetic diagnosis of NDDs.
format Online
Article
Text
id pubmed-8858550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88585502022-02-23 Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders Álvarez-Mora, María Isabel Sánchez, Aurora Rodríguez-Revenga, Laia Corominas, Jordi Rabionet, Raquel Puig, Susana Madrigal, Irene Orphanet J Rare Dis Research BACKGROUND: Neurodevelopmental disorders (NDDs) are a group of heterogeneous conditions, which include mainly intellectual disability, developmental delay (DD) and autism spectrum disorder (ASD), among others. These diseases are highly heterogeneous and both genetic and environmental factors play an important role in many of them. The introduction of next generation sequencing (NGS) has lead to the detection of genetic variants in several genetic diseases. The main aim of this report is to discuss the impact and advantages of the implementation of NGS in the diagnosis of NDDs. Herein, we report diagnostic yields of applying whole exome sequencing in 87 families affected by NDDs and additional data of whole genome sequencing (WGS) from 12 of these families. RESULTS: The use of NGS technologies allowed identifying the causative gene alteration in approximately 36% (31/87) of the families. Among them, de novo mutation represented the most common cause of genetic alteration found in 48% (15/31) of the patients with diagnostic mutations. The majority of variants were located in known neurodevelopmental disorders genes. Nevertheless, some of the diagnoses were made after the use of GeneMatcher tools which allow the identification of additional patients carrying mutations in THOC2, SETD1B and CHD9 genes. Finally the use of WGS only allowed the identification of disease causing variants in 8% (1/12) of the patients in which previous WES failed to identify a genetic aetiology. CONCLUSION: NGS is more powerful in identifying causative pathogenic variant than conventional algorithms based on chromosomal microarray as first-tier test. Our results reinforce the implementation of NGS as a first-test in genetic diagnosis of NDDs. BioMed Central 2022-02-19 /pmc/articles/PMC8858550/ /pubmed/35183220 http://dx.doi.org/10.1186/s13023-022-02213-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Álvarez-Mora, María Isabel
Sánchez, Aurora
Rodríguez-Revenga, Laia
Corominas, Jordi
Rabionet, Raquel
Puig, Susana
Madrigal, Irene
Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders
title Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders
title_full Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders
title_fullStr Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders
title_full_unstemmed Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders
title_short Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders
title_sort diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858550/
https://www.ncbi.nlm.nih.gov/pubmed/35183220
http://dx.doi.org/10.1186/s13023-022-02213-z
work_keys_str_mv AT alvarezmoramariaisabel diagnosticyieldofnextgenerationsequencingin87familieswithneurodevelopmentaldisorders
AT sanchezaurora diagnosticyieldofnextgenerationsequencingin87familieswithneurodevelopmentaldisorders
AT rodriguezrevengalaia diagnosticyieldofnextgenerationsequencingin87familieswithneurodevelopmentaldisorders
AT corominasjordi diagnosticyieldofnextgenerationsequencingin87familieswithneurodevelopmentaldisorders
AT rabionetraquel diagnosticyieldofnextgenerationsequencingin87familieswithneurodevelopmentaldisorders
AT puigsusana diagnosticyieldofnextgenerationsequencingin87familieswithneurodevelopmentaldisorders
AT madrigalirene diagnosticyieldofnextgenerationsequencingin87familieswithneurodevelopmentaldisorders